Emseubaio shares jump on KOSDAQ debut, nearly double the IPO price by midday
In short
Emseubaio (엠에스바이오) began trading on the KOSDAQ on 22 October with shares up 89.10% from the 7,800 won offer price at 09:02. By 12:35 the stock was at 15,510 won, up 98.85%, with 722.66 billion won in trading value, according to Seoul Shinmun.
Read the full story 2 min read
Emseubaio (엠에스바이오) began trading on the KOSDAQ on 22 October, and its shares rose sharply on the first day. Korea Economic Daily reported that at 09:02 the stock traded at 14,750 won, up 89.10% from the offer price of 7,800 won. Seoul Economic Daily reported that at 09:22 it stood at 13,610 won, up 74.49%. [ 1 , 2 ]
Seoul Economic Daily said the stock opened at 16,000 won, more than double the offer price, then fell on profit-taking after listing, about 15% below the opening price at the time of its report. By 12:35, Seoul Shinmun reported, the stock was at 15,510 won, up 7,710 won or 98.85%. About 45.17 million shares had changed hands, worth 722.66 billion won, the highest trading value in the KOSDAQ top-traded group it listed. Seoul Shinmun said its article was written with generative AI. [ 2 , 4 ]
The offer price was set at 7,800 won, the top of the 6,800-7,800 won target range, after an institutional demand forecast that drew a subscription ratio of 1,096.56 to 1. The retail subscription ratio was 1,538.51 to 1, and about 6.0152 trillion won in subscription deposits was placed, Korea Economic Daily reported. Seoul Economic Daily said the institutional forecast ran from 28 September to 2 October, and that 30.6% of institutional investors by order volume pledged not to sell for at least 15 days after listing. It said this was the second-highest such rate among KOSDAQ offerings completed since September, after Melcon (멜콘) at 36.07%. [ 1 , 2 ]
Emseubaio was founded in 2015. It develops and makes medical products using human tissue and biomaterials to help regenerate skin and bone. Last year it had revenue of 23.787 billion won and operating profit of 8.558 billion won. Seoul Economic Daily said operating profit was up about 42.9% from 5.99 billion won in 2024. [ 1 , 2 ]
The company plans to use the proceeds for a new plant in Ochang, North Chungcheong, expanded production facilities and building an overseas business base. Seoul Economic Daily added that it aims to expand in places such as the United States and Vietnam and to pursue clinical trials and commercialisation of new products. A second Seoul Economic Daily article, available only as a headline, linked the first-day gain of about 80% to expectations of growth in the equity capital market. [ 1 , 2 , 3 ]
Why it matters
The outlets present the debut as one of strong investor demand, citing oversubscribed institutional and retail offerings. The documents do not say whether the gains lasted beyond midday.
Key facts
- Emseubaio listed on the KOSDAQ on 22 October with an offer price of 7,800 won, the top of its 6,800-7,800 won target range. [ 1 , 2 ]
- The institutional demand forecast drew a subscription ratio of 1,096.56 to 1, and the retail subscription ratio was 1,538.51 to 1, with about 6.0152 trillion won in subscription deposits. [ 1 ]
- Seoul Economic Daily reported an opening price of 16,000 won, more than double the offer price, followed by profit-taking. [ 2 ]
- At 09:02 the stock traded at 14,750 won, up 89.10% from the offer price. [ 1 ]
- At 12:35 the stock traded at 15,510 won, up 98.85%, with 45,174,031 shares and 722.66 billion won changing hands. [ 4 ]
- Of institutional investors by order volume, 30.6% pledged not to sell for at least 15 days after listing, the second-highest rate among KOSDAQ offerings completed since September after Melcon (멜콘) at 36.07%. [ 2 ]
- The company said it will use the proceeds for a new plant in Ochang, North Chungcheong, expanded production facilities and building an overseas business base. [ 1 , 2 ]
Confirmed by several sources
- Emseubaio shares rose sharply on their first day on the KOSDAQ, 22 October, from the 7,800 won offer price. [ 1 , 2 , 3 , 4 ]
- The offer price was set at 7,800 won, the upper end of the 6,800-7,800 won range. [ 1 , 2 ]
- Emseubaio, founded in 2015, develops and makes medical products using human tissue and biomaterials to help regenerate skin and bone; last year it had revenue of 23.787 billion won and operating profit of 8.558 billion won. [ 1 , 2 ]
- The company plans to use the listing proceeds for a new plant in Ochang, North Chungcheong, expanded production facilities and an overseas business base. [ 1 , 2 ]
Still unclear
- Where the stock will settle after the first day. The documents give prices only up to 12:35 and the percentage gain ranged from about 74% to about 99% during the morning.
- Why the shares rose. Only the headline of one Seoul Economic Daily article links the rise to expectations of growth in the equity capital market (ECM); its text was not available.
What local media are saying
Timeline, local time
- Emseubaio trades at 14,750 won, up 89.10% from the offer price. [ 1 ]
- The stock is at 13,610 won, up 74.49%, about 15% below its 16,000 won opening price. [ 2 ]
- Seoul Economic Daily headlines the gain as 80%. [ 3 ]
- The stock is at 15,510 won, up 98.85%, with 722.66 billion won in trading value. [ 4 ]